Fasting or Random Glucose Testing? Navigating the New Rules for Cancer Therapy–Induced Hyperglycemia

As cancer treatment becomes increasingly sophisticated, clinicians are encountering a growing metabolic challenge. Cancer therapy–induced hyperglycemia has emerged as an important concern with the expanding use of immunotherapies and targeted therapies. In some patients, hyperglycemia develops gradually. In others, particularly those receiving immune checkpoint inhibitors, severe diabetes and diabetic ketoacidosis (DKA) can emerge rapidly and without warning.

Recognizing these risks, the American Diabetes Association (ADA) expanded its recommendations in the 2026 Standards of Care, providing more detailed guidance on glucose monitoring in patients receiving cancer therapies associated with hyperglycemia. Importantly, the recommendations emphasize that the optimal monitoring strategy depends on the mechanism of the anticancer agent. Understanding when to use fasting glucose testing versus random glucose testing is now essential for both oncology and diabetes care teams.

Table of Contents

• Why modern cancer treatments cause hyperglycemia
• Random glucose monitoring for checkpoint inhibitors
• Fasting glucose testing for PI3Kα and mTOR inhibitors
• Implementing the 2026 ADA recommendations
• Clinical implications for multidisciplinary care
• FAQs

Why Modern Cancer Treatments Cause Hyperglycemia

Several modern cancer therapies interfere directly or indirectly with glucose metabolism. However, not all drug classes create the same pattern of risk.

Immune checkpoint inhibitors, including PD-1, PD-L1, and CTLA-4 inhibitors, can trigger autoimmune destruction of pancreatic beta cells. Although this complication is relatively uncommon, it can lead to abrupt insulin deficiency and life-threatening DKA. Because onset may be sudden, routine surveillance becomes critical.

In contrast, targeted therapies such as phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitors and mammalian target of rapamycin (mTOR) inhibitors cause hyperglycemia through insulin resistance and impaired glucose signaling pathways. Hyperglycemia is considerably more common with these agents and often follows a predictable timeline after treatment initiation.

Consequently, monitoring strategies must be tailored to the underlying mechanism. A one-size-fits-all approach may miss serious complications or create unnecessary testing burdens.

Random Glucose Monitoring for Checkpoint Inhibitors

The 2026 ADA recommendations support routine random plasma glucose monitoring in patients receiving immune checkpoint inhibitors. This guidance reflects the unique nature of checkpoint inhibitor–associated diabetes.

Unlike traditional type 2 diabetes, checkpoint inhibitor–induced diabetes can develop rapidly between clinic visits. Patients may present with severe hyperglycemia, ketosis, or DKA despite previously normal glucose levels. Therefore, relying solely on fasting measurements may delay recognition of an evolving emergency.

Random glucose testing offers several advantages in oncology settings. First, it can be incorporated into routine laboratory assessments performed during treatment visits. Second, it allows clinicians to identify unexpected glucose elevations regardless of meal timing. Third, abnormal findings can prompt immediate evaluation for symptoms such as polyuria, polydipsia, fatigue, weight loss, or nausea.

The ADA also highlights the importance of educating patients and caregivers about warning signs of hyperglycemia and DKA. Early symptom recognition remains an essential component of risk reduction.

For patients receiving checkpoint inhibitors, clinicians should maintain a high index of suspicion even when baseline glucose levels are normal. Rapid-onset diabetes may occur weeks or months after therapy begins, making ongoing surveillance particularly important.

Fasting Glucose Testing for PI3Kα and mTOR Inhibitors

While random glucose testing plays a central role for checkpoint inhibitors, fasting plasma glucose monitoring is generally preferred for patients receiving PI3Kα and mTOR inhibitors.

These targeted therapies disrupt insulin signaling pathways that regulate glucose uptake and metabolism. As a result, fasting glucose measurements provide a more consistent and sensitive assessment of treatment-related metabolic changes.

Clinical trials have demonstrated high rates of hyperglycemia with PI3Kα inhibitors, particularly alpelisib. In some studies, hyperglycemia emerged within days to weeks after treatment initiation. Therefore, the highest-risk period typically occurs early in therapy.

The ADA recommends structured monitoring schedules during these vulnerable treatment windows. Frequent fasting assessments allow clinicians to identify worsening glycemia before severe complications develop. Early intervention may include dietary counseling, glucose-lowering medications, dose adjustments, or referral to endocrinology specialists.

Importantly, baseline metabolic risk factors should also be considered. Patients with obesity, prediabetes, type 2 diabetes, metabolic syndrome, or elevated hemoglobin A1C may require more intensive monitoring protocols.

Implementing the 2026 ADA Recommendations

Successful implementation of the new recommendations requires collaboration across oncology and diabetes care teams.

Before initiating high-risk therapies, clinicians should obtain baseline glucose measurements and assess preexisting metabolic conditions. Baseline hemoglobin A1C can help identify undiagnosed diabetes or prediabetes that may increase treatment-related risks.

During treatment, monitoring frequency should reflect both the therapeutic agent and patient-specific risk factors. Random glucose testing may be incorporated into routine oncology visits for checkpoint inhibitor recipients, while scheduled fasting assessments are particularly valuable for patients receiving PI3Kα or mTOR inhibitors.

Electronic health record alerts, standardized monitoring protocols, and multidisciplinary care pathways can further improve adherence to screening recommendations. These systems help ensure that abnormal results receive timely follow-up and intervention.

Additionally, patient education should begin before treatment starts. Individuals who understand the symptoms of hyperglycemia are more likely to seek prompt medical attention when concerns arise.

Clinical Implications for Multidisciplinary Care

The increasing use of immunotherapies and targeted therapies means that treatment-related hyperglycemia will become an increasingly common clinical challenge. The 2026 ADA recommendations recognize that different cancer treatments create distinct metabolic risks requiring individualized monitoring approaches.

For checkpoint inhibitors, routine random glucose testing helps identify potentially catastrophic autoimmune diabetes and DKA. Meanwhile, structured fasting glucose monitoring remains the preferred strategy for patients receiving PI3Kα and mTOR inhibitors, especially during high-risk periods shortly after treatment initiation.

Ultimately, early detection allows for timely intervention, improved treatment continuity, and better patient outcomes. As oncology and endocrinology continue to intersect, proactive glucose monitoring should become a standard component of comprehensive cancer care.

Conclusion

The updated 2026 ADA guidance provides a practical framework for managing hyperglycemia associated with cancer treatment. Rather than applying a universal monitoring strategy, clinicians should tailor glucose testing based on the specific anticancer therapy involved. Random glucose monitoring is particularly valuable for checkpoint inhibitors because of the risk of sudden-onset diabetes and DKA. Conversely, fasting glucose assessments offer a structured and effective approach for patients receiving PI3Kα and mTOR inhibitors. By adopting these evidence-based recommendations, healthcare teams can improve safety, detect complications earlier, and support optimal cancer treatment outcomes.

FAQs

Why is treatment-related hyperglycemia becoming more common in oncology care?

The growing use of immunotherapies and targeted therapies has increased the number of patients at risk for treatment-related hyperglycemia and therapy-induced diabetes.

Why does the ADA recommend random glucose testing for checkpoint inhibitors?

Checkpoint inhibitors can cause sudden autoimmune diabetes and DKA. Random glucose testing helps detect unexpected elevations during routine oncology visits.

Which cancer drugs commonly require fasting glucose monitoring?

PI3Kα inhibitors, such as alpelisib, and mTOR inhibitors are commonly associated with hyperglycemia that is best monitored using fasting glucose measurements.

Can patients without diabetes develop severe hyperglycemia during cancer treatment?

Yes. Even individuals with no prior history of diabetes may develop significant hyperglycemia or diabetes while receiving certain cancer therapies.

What symptoms should prompt urgent evaluation?

Excessive thirst, frequent urination, unexplained weight loss, fatigue, nausea, vomiting, or signs of DKA should prompt immediate medical assessment.

Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.